右美沙芬滥用风险分析

doi:10.19803/j.1672-8629.20220376

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (10): 1097-1099.
DOI: 10.19803/j.1672-8629.20220376

右美沙芬滥用风险分析

王丹, 吴晨, 任经天

国家药品监督管理局药品评价中心,国家药品监督管理局药物警戒研究与评价重点实验室,北京 100022

收稿日期:2022-07-08 出版日期:2022-10-15 发布日期:2022-10-17
作者简介:王丹,女,硕士,主任药师,药物警戒与药事管理。
基金资助:
重大新药创制国家科技重大专项2017年度（2017ZX09101001-001-003）

Risk analysis of dextromethorphan abuse

WANG Dan, WU Chen, REN Jingtian

Center for Drug Reevaluation, NMPA/ NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100022, China

Received:2022-07-08 Online:2022-10-15 Published:2022-10-17

摘要/Abstract

摘要： 目的探讨右美沙芬的滥用风险,为临床合理用药提供依据。方法分析1999年1月1日至2020年12月31日中国知网,万方数据中文献报道及世界卫生组织药品不良反应数据库中有关右美沙芬滥用病例情况及特征,讨论导致右美沙芬滥用风险的原因和监管部门采取措施的考量因素。结果和结论 右美沙芬单方制剂存在非医疗目的滥用风险,包括在青少年人群中滥用。非处方药右美沙芬易于购买及自我药疗不当可增加滥用风险。

关键词: 右美沙芬, 药物滥用, 药品不良反应, 风险分析

Abstract: Objective To explore the risk of dextromethorphan abuse and provide basis for clinical rational drug use. Methods The occurrence and characteristics of dextromethorphan abuse cases in literature reports in CNKI and Wanfang from 1999 to 2020 and related drug safety databases were analyzed. The causes of dextromethorphan abuse and the measures taken by the regulatory authorities were discussed. Results and Conclusion Dextromethorphan preparations are at risk of abuse for non-medical purposes, including in the adolescent. The availability of over-the-counter drugs and improper self-medication can increase the risk of abuse.

Key words: dextromethorphan, drug abuse, adverse drug reaction, risk analysis

中图分类号:

R969.3
R974

王丹, 吴晨, 任经天. 右美沙芬滥用风险分析[J]. 中国药物警戒, 2022, 19(10): 1097-1099.

WANG Dan, WU Chen, REN Jingtian. Risk analysis of dextromethorphan abuse[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1097-1099.

参考文献

[1] NMPA.Notice on publishing the first batch of national OTC drugs catalogue (western medicine, chinese patent medicine) [EB/OL].(1999-06-11)[2022-06-30]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/19990611010101639.html.
[2] DING Y, XIA L, DUAN L, et al.Clinical analysis of 13 patients with dextromethorphon dependence[J]. Chinese Journal of Drug Abuse Prevention and Treatment, 2021, 27(2): 155-158.
[3] NMPA. Announcement of the NMPA on the conversion of dextromethorphan hydrobromide oral monoprescription into prescription drugs (No. 151, 2021) [EB/OL]. (2021-12-16)[2022-06-23]. https://www.nmpa.gov.cn/yaopin/ypggtg/20211227162159192.html.
[4] QUAN DM.A case of forensic identification of mental disorders caused by abuse of dextromethorphan[C]. Proceedings of the 10th National Judicial Psychiatry Academic Conference, 2007: 355-357.
[5] HE RH, WANG XL, CHEN HL, et al.A case of dextromethorphan abuse[J]. Chinese Journal of Drug Dependence, 2008, 17(5): 399.
[6] DUAN L.Analysis of clinical characteristics of 27 cases of dextromethorphan abuse[C]. Proceedings of the 2015 National Symposium on drug abuse prevention and control and the 9th Symposium on drug abuse prevention and control in the mainland, Hong Kong and Macao, 2015: 340-344.
[7] CHEN YL, XU W.Juvenile poisoning caused by drug abuse of dextromethorphan hydrobromide[J]. Chinese Pediatric Emergency Medicine, 2017, 24(5): 388-390.
[8] XI W, LI SG.A case of severe drug dependence caused by dextromethorphan hydrobromide tablets[J]. Chinese Journal of Drug Abuse Prevention and Treatment, 2019, 25(1): 52.
[9] XU FQ, XU J, LIU ZS.Two cases of dependence caused by abuse of dextromethorphan hydrobromide[J]. Cardiovascular Disease Journal of Integrated Traditional Chinese and Western Medicine(Electronic), 2019, 7(12): 188.
[10] ZHANG XB.2 cases of drug addiction caused by repeated oral administration of dextromethorphan[J]. Chinese Journal of Drug Abuse Prevention and Treatment, 2020, 26(1): 34-35,42.
[11] XU J, SUN P, LIU Y, et al.A case of adult dextromethorphan hydrobromide drug abuse and literature review[J]. Chinese Journal of Drug Dependence, 2020, 29(1): 78-79.
[12] SCHWARTZ RH.Adolescent abuse of dextromethorphan[J]. Clin Pediatr (Phila), 2005, 44(7): 565-568.
[13] CAO J.Abuse of dextromethorphan is potentially dangerous and may cause death[J]. Foreign Pharmaceutical News, 2005(12): 33-35.
[14] Drug Enforcement Administration.Dextromethorphan (Street Names: DXM, CCC, Triple C, Skittles, Robo, Poor Man's PCP)[EB/OL]. [2022-06-30].https://www.deadiversion.usdoj.gov/drug_chem_info/dextro_m.pdf.
[15] FDA. Memorandum from September 14, 2010, DSaRM Advisory Committee Meeting[EB/OL]. (2010-08-23)[2022-06-23].https://www.fda.gov/advisory-committees/human-drug-advisory-committees/drug-safety-and-risk-management-advisory-committee.
[16] IRWIN RS.Diagnosis and management of cough: ACCP evidence-based clinical practice guidelines[J]. Chest, 2006, 129(1): 1S-292S.
[17] LI DK, JIN YY, TANG G, et al.Martindale—The Complete Drug Reference[M]. Beijing: Chemical Industry Press, 2008: 1225
[18] SFDA. Notice on printing and distributing 6 technical documents about the guiding principles for the evaluation of the conversion of prescription drugs to OTC drugs (for Trial Implementation) - Annex 6[EB/OL]. (2012-11-14)[2022-06-23]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20121114120001923.html.

右美沙芬滥用风险分析

Risk analysis of dextromethorphan abuse

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.